Returns Breakdown
| Return on Investment | (171.35) | |
| Return on Assets | (0.56) | |
| Return on Equity | (1.06) | |
| Return Capital | (0.74) | |
| Return on Sales | (4.49) |
Should you shadow Atara Biotherapeutics (USA Stocks:ATRA) insiders in March?
 | By Rifka Kats | Macroaxis Story |
They say timing is everything in the stock market, and for shareholders of Atara Biotherapeutics, a biotechnology firm in the healthcare sector, this adage rings particularly true. With a 52-week high of $4.68, the stock is currently trading at a mere $0.83, a significant drop that may be causing investors to question their holdings. The company's estimated earnings per share (EPS) for the next year is projected to be a loss of $1.48, and with a short ratio of 1.9, it's clear that some investors are betting on the stock's further decline. However, with an analyst overall consensus rating of 'Hold' and a possible upside price of $13.08, the question remains: Is now the optimal moment to liquidate Atara Biotherapeutics stock? Currently, Atara Biotherapeutics' Average Equity is projected to see significant growth, based on reports from the past few years. The company's Enterprise Value for the current year is expected to rise to approximately $360.9 million. However, the Net Income Per Employee is predicted to decrease to -$663.8K. This article aims to predict the future value of Atara Biotherapeutics using technical analysis. So, what should investors of Atara Biotherapeutics anticipate in March?
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
With a high Coefficient of Variation at 1.4K and a downside variance of 270.32, Atara Biotherapeutics stock exhibits a significant level of risk. The company's negative earnings per share (EPS) estimate for the current year stands at a loss of 2.54, hinting at financial struggles. Despite Wall Street's target price of 4.83, considering the company's current risk-adjusted performance of 0.0487, it may be an optimal moment for investors to liquidate Atara Biotherapeutics stock and mitigate potential losses.
Important Points
Institutional investors, such as insurance companies, hold over 90.0% of Atara Biotherapeutics shares. This institutional ownership refers to the portion of Atara Biotherapeutics equity owned by entities like mutual funds, pension funds, insurance companies, investment firms, and foundations that manage money on behalf of others. For our latest analysis of Atara, including its current ownership details, please refer to our recent ownership diagnostics report.There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Atara Biotherapeutics. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Predictive Modules for Atara Biotherapeutics
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Atara Biotherapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
How important is Atara Biotherapeutics's Liquidity
Atara Biotherapeutics financial leverage refers to using borrowed capital as a funding source to finance Atara Biotherapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Atara Biotherapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Atara Biotherapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Atara Biotherapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Atara Biotherapeutics's total debt and its cash.
Atara Biotherapeutics Gross Profit
Atara Biotherapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Atara Biotherapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Atara Biotherapeutics Gross Profit growth over the last 10 years. Please check Atara Biotherapeutics' gross profit and other fundamental indicators for more details.
A Deeper Perspective
Atara Biotherapeutics is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to ensure that related market timing strategies are aligned with all the expectations about Atara Biotherapeutics implied risk. Atara Biotherapeutics is a potential penny stock. Although Atara Biotherapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Atara Biotherapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Atara instrument if you perfectly time your entry and exit.However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
"Never try to catch a falling knife," is a saying that rings true when considering Atara Biotherapeutics. The company's stock, currently trading at a typical day price of $0.83, is far below the Wall Street target price of $4.83, indicating a potential upside of 27.27%. However, with a high probability of bankruptcy at 95.04%, and a negative return on equity of 4.26%, the financial health of the company is in question. Despite a strong current ratio of 5.28X and substantial cash and equivalents of $331.31M, the company's high downside deviation of 16.44 and a negative EPS estimate for the current year of $2.54 suggest that now might indeed be the optimal moment to liquidate Atara Biotherapeutics stock. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Atara Biotherapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.